Dementia extra widespread in sufferers with RA receiving csDMARDs vs b/tsDMARDs

December 07, 2022

2 min learn

Sattui studies receiving analysis assist from AstraZeneca. Please see the examine for all different authors’ related monetary disclosures.

We had been unable to course of your request. Please attempt once more later. If you happen to proceed to have this concern please contact

Dementia is extra widespread in sufferers with rheumatoid arthritis who obtain standard artificial illness modifying anti-rheumatic medication vs. biologics or focused artificial therapies, in keeping with knowledge.

“Neuroinflammation, a power means of native sustained irritation secondary to both intrinsic or systemic stimuli, is assumed to play an vital function within the improvement of dementia, notably Alzheimer’s dementia (AD),” Sebastian E. Sattui, MD, MS, of the College of Pittsburgh, and colleagues wrote in Seminars in Arthritis and Rheumatism. “The function of tumor necrosis factor-alpha (TNF-) within the improvement of dementia has been notably highlighted, elevating an curiosity for the potential protecting impact of TNF- inhibitors (TNFi).

Dementia is extra widespread in sufferers with RA who obtain standard artificial DMARDs vs. biologics or focused artificial DMARDs, in keeping with knowledge.

“Organic (eg, elevated proinflammatory cytokines, elevated blood-brain barrier permeability, untimely immunosenescence) and medical elements (eg, power ache, despair, incapacity, heart problems) signify potential and biologically-plausible hyperlinks between cognitive decline and rheumatoid arthritis,” they added. “Few research have investigated the impact of illness modifying antirheumatic medication (DMARDs), together with TNFi-bDMARDs, and incident dementia in sufferers with RA.”

To research the danger for dementia in sufferers with RA receiving biologic or focused artificial DMARDs, in contrast with standard artificial DMARDs, Sattui and colleagues evaluated CMS claims knowledge from 2006 to 2017. To be included, sufferers should have been recognized with RA and continued enrollment in Medicare price for service for a minimum of 12 months previous to the baseline interval of illness presentation. Sufferers had been excluded if they’d dementia at baseline or different rheumatic ailments. Sufferers with end-stage renal illness, most cancers and HIV or AIDS had been additionally excluded.

The researchers used pharmacy and medical claims knowledge to determine durations of drug publicity. Particularly, they assessed biologic or focused artificial DMARDs, with or with out standard artificial DMARDs, or standard artificial DMARDs alone. Main outcomes included incident dementia or a prescription for dementia-specific medicine. The researchers used diagnostic and drug codes to establish these instances.

The evaluation included 141,326 eligible sufferers with RA. In all, there have been 233,271 DMARD initiations and three,794 instances of incident dementia through the examine interval.

In accordance with the researchers, the incident price of dementia was two per 100 person-years for sufferers receiving standard artificial DMARDs (95% CI, 1.9-2.1) vs. 1.3 per 100 person-years for sufferers utilizing any biologic or focused artificial DMARD (95% CI, 1.2-1.4). This resulted in a 19% decrease danger for sufferers receiving biologic or focused artificial DMARDs, in contrast with these receiving standard artificial DMARDs (HR = 0.81; 95% CI, 0.76-0.87).

“Amongst Medicare beneficiaries with RA, b/tsDMARDs had been related to a decrease danger of incident dementia when in comparison with sufferers on csDMARDs solely even after adjusting for related covariates,” Sattui and colleagues wrote. “The decreased danger of incident dementia was noticed no matter kind of b/tsDMARDs use and was constant within the subgroup evaluation of sufferers who had been taking [methotrexate] beforehand or sufferers with or with out [cardiovascular] danger elements or [cardiovascular disease].”


  • Newcombe EA, et al. J Neuroinflamm. 2015;doi: 10.1186/s12974-018-1313-3
  • Pasqualetti G, et al. Curr Neurol Neurosci Rep. 2015;doi: 10.1007/s11910-015-0531-7
  • Torres-Acosta N, et al. J Alzheimer’s Dis. 2020;doi: 10.3233/JAD-200711


Leave a Reply

Your email address will not be published. Required fields are marked *